Dr. Ilyas Sahin, MD, is a medical oncologist at Massachusetts General Hospital (MGH), a member of the Termeer Center for Targeted Therapies and the Center for Gastrointestinal Cancers. He specializes in early-phase clinical trials for solid tumors, with a focus on advancing novel therapies through Phase 1 drug development, including targeted therapies and immunotherapies.

Dr. Sahin has a strong clinical and research interest in upper gastrointestinal cancers, including gastric and esophageal cancers. He also maintains a dedicated focus on hepatocellular carcinoma (HCC) and liver metastases from other tumors, particularly within early-phase clinical research.

At MGH, Dr. Sahin is committed to translating groundbreaking scientific discoveries into personalized treatments for patients. Known for his compassionate and comprehensive approach to care, he integrates cutting-edge advances into individualized therapy plans, aiming to improve outcomes for patients with complex and challenging cancers.